NEW YORK (GenomeWeb News) – Cellectis today announced the licensing of certain patents to Novartis covering certain uses of homologous recombination.
The deal grants the Swiss-based pharmaceutical firm patents for the family WO 90/11354. The technology belongs to the Pasteur Institute and Cellectis owns exclusive rights to them.
The technology allows researchers to introduce new characteristics into genomes.
Financial terms of the deal were not disclosed.